Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.
You may also be interested in...
Dropping Ocrelizumab Could Be Good For Biogen Idec's Cash Flow
The motion-picture-industry themed ocrelizumab RA program won't be taking home any awards with the FILM study on clinical hold and the SCRIPT trial halted after deaths from infection.
Biogen-Idec Prevails Over Genentech In Arbitration For Control Of Rituximab
Arbitrator rules that 2003 merger combining Biogen and Idec does not forfeit company’s rituximab rights via a change-of-control.
New Business Models Needed For Drug Diagnostic Partnerships
The industry is stymied by outmoded partnership models that don’t adequately value the knowledge of diagnostic makers.